Potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases (CDKs) 1, 2, 5, 7 and 9. Two to four-fold more potent inhibitor of CDKs than (R)-roscovitine (Prod. No. BML-CC205). Induces apoptotic cell death more potently than (R)-roscovitine. Equally potent inhibitor of CDKs as (R)-CR8. Less potent glycogen synthase kinase (GSK-3α/β) inhibitor than (R)-CR8.
Product Details
| Formula: | C24H29N7O |
| |
| MW: | 431.5 |
| |
| Source: | Synthetic. |
| |
| CAS: | 1084893-56-0 |
| |
| Purity: | ≥97% (NMR) |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in DMSO or 100% ethanol. |
| |
| Shipping: | Ambient Temperature |
| |
| Short Term Storage: | +4°C |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light. Packaged under inert gas. |
| |
| Scientific Background: | The 20 cyclin-dependent kinases (CDKs) belong to an extensively studied and well-conserved family of kinases. Experiments have shown that thirteen of the 20 CDKs are activated by the binding of the regulatory partner cyclin. In conjunction with cyclins and through complex pathways, CDKs regulate diverse key transitions of the cell division cycle. A plethora of abnormalities in the regulation and activity of CDKs have been described in various tumors. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases: K. Bettayeb, et al.; Oncogene
27, 5797 (2008),
Abstract;
Related Products
